<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704702</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FRC-CT-102</org_study_id>
    <secondary_id>CA16652</secondary_id>
    <nct_id>NCT02704702</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and
      rosuvastatin when coadministered or administered alone as a single dose or as multiple doses
      to healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, 6-sequence, 3-period, 3-way crossover study. Within each
      period, randomized subjects will be 2 dosing regimens with the same drug(fimasartan or
      rosuvastatin) or study drug combination(fimasartan+rosuvastatin) on day 1 and quaque die(qd)
      from day 4 to day 10. After day 1 and day 10 dosing will be followed by pharmacokinetic
      sampling for 48 hours or 72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve</measure>
    <time_frame>After day 1 and day 10 dosing will be followed by PK sampling for 48 hours or 72 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration</measure>
    <time_frame>After day 1 and day 10 dosing will be followed by PK sampling for 48 hours or 72 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum observed plasma concentration</measure>
    <time_frame>After day 1 and day 10 dosing will be followed by PK sampling for 48 hours or 72 hours.</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan + Rosuvastatin</intervention_name>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Caucasian male 19-55 years of age.

          2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.

          3. Medically healthy with no clinically significant medical history.

          4. Understands the study procedures in the Informed consent form (ICF), and be willing
             and able to comply with the protocol.

        Exclusion Criteria:

          1. History or presence of clinically significant medical or psychiatric condition or
             disease.

          2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or hepatitis C virus (HCV).

          3. Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at
             screening.

          4. Plasma donation within 7 days prior to the first dose of study drug.

          5. Participation in another clinical trial within 28 days prior to the first dose of
             study drug(s).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Sterling, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celelion, Inc.</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 26, 2017</submitted>
    <returned>January 9, 2018</returned>
    <submitted>February 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

